Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
Why invest in NANO?
Nanobiotix SA: THE INVESTMENT CASE

Nanobiotix technology has "blockbuster potential", according to American investment bank

Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
Patient undergoing radiotherapy
INVESTMENT OVERVIEW: NANO The Big Picture
The breakthrough amplifies the effect of radiotherapy

Nanoparticles with mega potential - that’s how the biotech team at American investment bank Jefferies described Nanobiotix SA (EPA:NANO), which has developed a unique method of amplifying radio-therapy.

Jefferies Wednesday initiated coverage of stock in the company with a ‘buy’ rating and €26 a share price target. That’s 32% above the current price of €19.66.

The company has developed NBTXR3, which is injected directly into solid tumours to amplify the effects of tumour shrinking treatment.

It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.

Seven cancers...

It is now being trialled across seven separate cancer indications.

Analyst Peter Welford believes the treatment has “blockbuster potential” if is widely adopted.

“As a one-time treatment that is fully compatible with standard radiotherapy protocols, NBTXR3 could be used in around 60% of radiotherapy-treated cancers,” he said.

The analyst estimates worldwide peak sales for use in soft tissue sarcoma (STS) could be in the order of US$175mln, while head and neck cancer is a far bigger market for Nanobiotix at US$550mln a year.

Other uses...

However, the product could generate US$1.4bn a year for the business if it is more widely adopted, Welford reckons.

The current valuation only takes into account NBTXR3’s use in STS and head and neck cancer.

“NBTXR3 could also act as an in situ vaccine with radiotherapy to aid transforming tumours from ‘cold’ to ‘hot’ with highly immunogenic targets, suggesting a potentially lucrative combo with immuno-oncology agents,” the analyst pointed out.

View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

1518096073_biotechLatest.jpg
February 08 2018
The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests
cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use